Should bisphosphonates be utilized in the adjuvant setting for breast cancer?

By Lipton Allan  

Breast Cancer Research and Treatment, Vol. 122, Iss. 3, 2010-08 ,pp. : 627-636

Springer Publishing Company

Access to resources Recommend Favorite

Is cognitive dysfunction a complication of adjuvant chemotherapy in the older patient with breast cancer?

By Hurria Arti   Lachs Mark  

Breast Cancer Research and Treatment, Vol. 103, Iss. 3, 2007-07 ,pp. : 259-268

Springer Publishing Company

Access to resources Recommend Favorite

Can bone markers guide more effective treatment of bone metastases from breast cancer?

By Clemons Mark   Cole David   Gainford Mary  

Breast Cancer Research and Treatment, Vol. 97, Iss. 1, 2006-05 ,pp. : 81-90

Springer Publishing Company

Access to resources Recommend Favorite

Which is better in neoadjuvant treatment of breast cancer? Taxane followed by anthracyline or vice versa

By Altundag Kadri   Altundag Ozden   Baptista Mauricio   Atik Mustafa  

Breast Cancer Research and Treatment, Vol. 97, Iss. 2, 2006-05 ,pp. : 221-221

Springer Publishing Company

Access to resources Recommend Favorite

Are medical oncologists biased in their treatment of the large woman with breast cancer?

By Madarnas Y.  

Breast Cancer Research and Treatment, Vol. 66, Iss. 2, 2001-03 ,pp. : 123-133

Springer Publishing Company

Access to resources Recommend Favorite